menu
    • menu
    [{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ZEN003694","moa":"BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zenith Epigenetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Not Applicable"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Ipilimumab","moa":"BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Zenith Epigenetics \/ National Cancer Institute"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Talazoparib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Pfizer"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Talazoparib","moa":"BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Not Applicable"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ZEN003694","moa":"BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ National Cancer Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by Zenith Epigenetics

    Menu

    Zenith Epigenetics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zenith Epigenetics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694,Talazoparib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Tria...

                            Details : ZEN-3694 (ZEN003694), orally bioavailable small molecule, in initro studies selectively binds to BET proteins with >20 fold selectivity over non-BET bromodomains inhibiting interaction of acetylated histone peptide with IC50 values in low nM range.

                            Brand Name : ZEN-3694

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 06, 2022

                            Lead Product(s) : ZEN003694,Talazoparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zenith Epigenetics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN-3694,Talazoparib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the Americ...

                            Details : The combination regimen of ZEN-3694 (ZEN003694) + talazoparib has shown promising clinical activity in a mTNBC patient population with significant unmet need. This combination is active with a manageable safety profile and warrants continued clinical eva...

                            Brand Name : ZEN003694

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 21, 2022

                            Lead Product(s) : ZEN-3694,Talazoparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zenith Epigenetics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN-3694,Talazoparib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

                            Details : The data from the Phase 1b/2 trial has shown that the ZEN003694 (ZEN-3694) plus talazoparib combination regimen induced durable responses in tumors of TNBC patients which do not harbor mutations in BRCA1/2.

                            Brand Name : ZEN003694

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 10, 2022

                            Lead Product(s) : ZEN-3694,Talazoparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zenith Epigenetics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN-3694,Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

                            Details : First clinical Study to Combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer.

                            Brand Name : ZEN-3694

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 05, 2020

                            Lead Product(s) : ZEN-3694,Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zenith Epigenetics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Zenith Epigenetics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN003694,Enzalutamide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs

                            Details : Merck, Pfizer, UCSF and Newsoara join the list of collaborators involved in Zenith's development of ZEN-3694 in epigenetic combination therapy programs.

                            Brand Name : ZEN-3694

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 29, 2020

                            Lead Product(s) : ZEN003694,Enzalutamide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth